Simris Group (SIMRIS) investor relations material

Executive summary

• Net revenue rose 167% year-over-year to SEK 424k, with significant improvements in EBITDA and EBIT, though both remain negative.

• Strategic focus on advancing ADC payload R&D, with new preclinical studies and innovation in payload design.

• Progress on divestment of Hammenhög assets, with two prospective buyers engaged and expected sale at book value.

• Board evaluating two strategic pathways: expanding core ADC platform or integrating an experienced ADC team for accelerated clinical development.

Financial highlights

• EBITDA improved by 41% to SEK -2,183k; EBIT improved by 23% to SEK -5,626k year-over-year.

• Result before tax was SEK -6,973k, slightly worse than SEK -6,795k last year.

• Cash flow from operating activities improved by 25% to SEK -3,967k.

• Cash at period end was SEK 10,759k, up 259% year-over-year.

• Equity at quarter end was SEK 5,486k, up from SEK -1,071k last year; solidity improved to 3.9%.

Outlook and guidance

• Board warns current cash reserves may not last through year-end; active efforts underway to secure new funding.

• Strategic direction decision expected in Q2, with focus on value creation and accelerated growth.